MACROTwenty-nine health systems plan to exit Medicare AdvantageSep 9, 2026
MACROCopper hits record $14,858.50 a ton as tariff stockpiling and global supply crunch convergeSep 9, 2026
CRYPTOIran relaxes foreign currency controls in quiet pivot toward cryptoSep 9, 2026
AMZNAmazon routes 360,000 annual scam inquiries through a new Alexa verification toolSep 9, 2026
AMZNGame-day deals: Ninja cooler hits 90-day low as NFL season opensSep 9, 2026
DEALSZAR 0.673 per share: GWWTF declares semi-annual cash dividend, payable 19 October 2026Sep 9, 2026
MACROTrump's rate-cut push may leave consumers worse off, experts saySep 9, 2026
DEALSUS Treasury sets $6bn ceiling on long-bond buybacks as Bessent moves to steady debt marketSep 9, 2026
MACROTwenty-nine health systems plan to exit Medicare AdvantageSep 9, 2026
MACROCopper hits record $14,858.50 a ton as tariff stockpiling and global supply crunch convergeSep 9, 2026
CRYPTOIran relaxes foreign currency controls in quiet pivot toward cryptoSep 9, 2026
AMZNAmazon routes 360,000 annual scam inquiries through a new Alexa verification toolSep 9, 2026
AMZNGame-day deals: Ninja cooler hits 90-day low as NFL season opensSep 9, 2026
DEALSZAR 0.673 per share: GWWTF declares semi-annual cash dividend, payable 19 October 2026Sep 9, 2026
MACROTrump's rate-cut push may leave consumers worse off, experts saySep 9, 2026
DEALSUS Treasury sets $6bn ceiling on long-bond buybacks as Bessent moves to steady debt marketSep 9, 2026

Five healthcare penny stocks drawing fresh attention as sector expands

Five names sit at the top of Benzinga's healthcare penny stock list, per analyst Chris Davis: Revive Therapeutics Ltd., Antares Pharma Inc., Medical Marijuana Inc., BIMI International Medical Inc., and Stem Cell Authority Ltd. Davis frames…

By Warren Ashby·Aug 20, 2026·2 min read·crypto·PFE · HOOD

Key takeaways

  • Benzinga analyst Chris Davis names five healthcare penny stocks drawing attention: Revive Therapeutics Ltd., Antares Pharma Inc., Medical Marijuana Inc., BIMI International Medical Inc., and Stem Cell Authority Ltd.
  • Davis bases the picks on an aging-population thesis and the claim that the coronavirus period depressed healthcare stock prices, creating buying opportunities.
  • The article divides the healthcare market into two segments: healthcare equipment and services, and pharmaceuticals, biotechnology and related life sciences.
  • Davis names five brokers suited to penny stock trading: Interactive Brokers, Plus500, Public.com, Robinhood, and TradeZero.
  • Benzinga warns that profitability in penny stocks can come at the expense of unprepared investors, noting these are shares of low-value companies.

Five names sit at the top of Benzinga's healthcare penny stock list, per analyst Chris Davis: Revive Therapeutics Ltd., Antares Pharma Inc., Medical Marijuana Inc., BIMI International Medical Inc., and Stem Cell Authority Ltd. Davis frames the picks around an aging-population thesis and a separate claim that the coronavirus period created buying opportunities by depressing healthcare stock prices broadly.

The source divides the healthcare market into two segments: healthcare equipment and services, and pharmaceuticals, biotechnology and related life sciences. Pfizer (NYSE: PFE) and Merck and Co. (NYSE: MRK) are cited as names that hold value during recessions. Gilead Sciences (NASDAQ: GILD) and Inovio Pharmaceuticals (NASDAQ: INO) attracted investor attention during the coronavirus period on vaccine-development activity. The smaller penny stocks on the list, Davis argues, piggybacked on that sector attention and drew new capital.

The mechanism worth examining before the price: when institutional money flows into large-cap biotech on a macro demographic thesis, smaller names in the same sector tend to collect spillover dollars from retail traders chasing percentage moves. Penny stocks are, per Benzinga's own framing, shares of low-value companies. The upside is real in some cases. So is the distance between what a motivated promoter holds and what a retail buyer reads in a summarized list. Benzinga acknowledges that profitability in this category "can come at the expense of unprepared investors."

Broker selection and execution costs

Davis names five brokers suited to this category: Interactive Brokers, Plus500, Public.com, Robinhood, and TradeZero. The baseline issue: not every broker accepts penny stock trades, and those that do may charge additional commissions depending on how difficult the stock is to source. For active short-term traders, Davis points to execution quality, interface design, and a real-time news feed as the key selection criteria.

Benzinga describes healthcare as a sector "always in demand." The macro premise is separate from the per-name risk. TradeZero enforces a minimum daily equity balance of $25,000 for pattern day traders. Plus500 carries its own regulatory disclosure: 81 percent of retail investor accounts lose money when trading CFDs with that provider.

Related reading

Share
Source: benzinga.com
© 2026 NewsMeter

Frequently asked

Which five healthcare penny stocks are on Benzinga's list?

The five are Revive Therapeutics Ltd., Antares Pharma Inc., Medical Marijuana Inc., BIMI International Medical Inc., and Stem Cell Authority Ltd.

Why does the analyst believe these penny stocks gained attention?

Davis argues that institutional money flowing into large-cap biotech on an aging-population thesis produced spillover into smaller sector names, which piggybacked on that attention and drew new retail capital.

What risks does the article highlight for penny stock investors?

It notes that profitability can come at the expense of unprepared investors, that not every broker accepts penny stock trades, and that some brokers charge extra commissions when a stock is difficult to source.

What trading requirements or disclosures apply to the named brokers?

TradeZero enforces a $25,000 minimum daily equity balance for pattern day traders, and Plus500 discloses that 81 percent of retail investor accounts lose money trading CFDs with it.

Which large-cap healthcare stocks does the article cite?

Pfizer and Merck and Co. are cited as names holding value during recessions, while Gilead Sciences and Inovio Pharmaceuticals drew attention during the coronavirus period on vaccine-development activity.